Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.

ABSTRACT:

Aims

The aim of this study is to use six previously described heart failure with preserved ejection fraction (HFpEF) phenotypes to describe differences in (i) the biological response to spironolactone, (ii) clinical endpoints, and (iii) patient-reported health status by HFpEF phenotype and treatment arm in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT).

Methods and results

We analysed 1767 patients in TOPCAT from the Americas. Using 11 clinical variables, patients were classified according to six HFpEF phenotypes previously identified in the I-PRESERVE and CHARM-Preserved studies. Kansas City Cardiomyopathy Questionnaire (KCCQ) measured health status. All phenotypes showed increase in potassium with spironolactone, alt

SUBMITTER: Flint KM 

PROVIDER: S-EPMC7261552 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature